CPRX

NEUTRALEarnings

Catalyst Pharmaceuticals, Inc.

2026-04-23

Price

$27.68

+6.71%

Score13.5Priority

Signals4/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume2.3xvs 20d avg

Analysis

Catalyst Pharmaceuticals is exhibiting High-Conviction Price Discovery, breaking out to all-time highs on 2.3x relative volume. This explosive move is fundamentally anchored by a massive Q4 earnings beat ($0.68 EPS vs $0.49 estimate) and robust 2026 revenue guidance ($615M-$645M) driven by its Firdapse and Agamree franchises. Within the current RISK_ON (EARNINGS) macro regime, CPRX's low PEG ratio and expanding M&A pipeline make it a prime target for institutional accumulation, perfectly confirming the strong ALPHA_MALE and BREAKOUT technical signals.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONBREAKOUTWEAK FINISH

Key Takeaways

Actionable Thesis: Ride the momentum of this high-conviction breakout as institutional buyers aggressively accumulate shares following strong earnings, raised guidance, and analyst price target hikes to $35.
Key Risk: The upcoming Q1 earnings report on May 6, 2026, where any deceleration in Agamree or Firdapse sales could trigger a sharp mean-reversion.
What to Watch: Monitor the $23.40 support level as a structural trailing stop, and watch for further M&A pipeline announcements which are currently fueling the bullish narrative.

← Back to 2026-04-23 View Full CPRX History →Yahoo Finance &nearr;